ClinicalTrials.Veeva

Menu

Prospective Longitudinal Monocentric Study to Evaluate the Feasibility of Syde® Digital Endpoints for Monitoring Patients With Progressive Supranuclear Palsy - Richardson Syndrome (PSP-R) (PROSPER-SYDE)

S

Sysnav Healthcare

Status

Not yet enrolling

Conditions

Progressive Supranuclear Palsy- Richardson Syndrome (PSP-R)

Study type

Observational

Funder types

Industry

Identifiers

NCT07389018
PR5030-76
2024-A02611-46 (Other Identifier)

Details and patient eligibility

About

The study aims to assess the feasibility/acceptability of real-world activity monitoring by the Syde® wearable device in PSP-R. The Syde® collected data will be compared to on-site conventional clinical endpoints, including functional capacity and cognitive assessments, as well as core scales assessments.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1.18 years old or older

2.Participants affiliated to, or beneficiary from, a social security.

3.Ambulant patients (i.e. able to walk 10 meters without assistance)

4.Signed informed consent form by the patient himself or, by caregivers if the patient is not capable to fill, date and sign the form due to fine motor function difficulties..

5.Possible or probable PSP-R according to MDS criteria 2017(Hoglinger et al., Mov Disorder, 2017).

Exclusion criteria

  1. Patients with extreme cognitive disorders that limit their understanding of the data collection process (training of device use and 4-week recording periods every 4 months, device return at the end of the study), tests to be performed including eye movement recording (every 8 months), the implication of the study and consent.
  2. Patients who do not tolerate to keep the sensors on their ankles.
  3. Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the lower limbs.
  4. A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion.
  5. Patients affected by any other disorder having a significant impact on gait or lower limb function.
  6. Participant covered by a legal protection measure (guardianship, curatorship or safeguarding of justice) or who is unable to express their consent.
  7. Absence of caregiver.

Trial contacts and locations

1

Loading...

Central trial contact

Ferial Toumi

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems